INTANGIBLE ASSETS Continued c. Product dossiers: Product dossiers have an average estimated useful life of 15 years 2011: 15 years.
In-process R&D: In-process R&D represents mainly the pipeline of products under development that were recognised on the acquisition of Arab Pharmaceutical Manufacturing Company and Hikma Pharma SAEEgypt.
The in-process R&D has an average estimated useful life of 15 years 2011: 15 years.
Trade name: Trade names were mainly recognised on the acquisition of Hikma Germany GmbH Germany, Arab Pharmaceutical Manufacturing Company, Promopharm, Savanna and Ibn Al Baytar.
The trade name recognised on the acquisition of Hikma Germany GmbH Germany is expected to have an indefinite economic useful life dueto its expected longevity.
The carrying value of Hikma Germany GmbH Germany trade name is $5,536,000 2011: $5,423,000.
The movement has arisen due to retranslation.
The trade names recognised on the acquisition of the other subsidiaries have useful lives that vary from3 to 20 years.
Software: Software intangibles mainly represent the Enterprise Resource Planning solution that is being implemented in different operations across the Group.
The software has an average estimated useful life of five years.
Other acquisition related intangibles: This mainly represents intangible assets recognised on the acquisition of Thymoorgan, which relate to its specialist manufacturing capabilities.
The estimated useful life varies from 10 years to an indefinite useful life.
The carrying value of assets with indefinite lives is $991,000 2011: $971,000.
The movement relates to retranslation at year end rates.
